Related Experiment Video
Updated: Jul 23, 2026
Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis
Published on: June 26, 2016
Identification and validation of synergistic drug strategies targeting macrophage polarization in triple-negative
Qi Qi1, Wenhao Yang1, Liang Li1
1Laboratory of Molecular Genetics of Aging & Tumor, Medicine School, Kunming University of Science and Technology, China.
Abstract:
Triple-negative breast cancer (TNBC) presents therapeutic challenges due to its immunosuppressive tumor microenvironment (TME) and limited targeted options. Analyzing scRNA-seq data from 24 TNBC patients using integrated transcriptomics, machine-learning, and pseudo-time trajectory mapping, we developed a macrophage differentiation-based classifier (MMDCSS) (CD93, CHI3L1, ZBTB20) with remarkable prognostic accuracy (C-index: 0.929, 3-year AUC: 0.907). Computational pharmacology identified finasteride as a ZBTB20 modulator (binding energy:7.7 kcal/mol) capable of reversing tumor-induced M2 macrophage polarization. Finasteride significantly enhanced doxorubicin efficacy ex vivo and in vivo by reprogramming the TME, reducing M2 macrophage infiltration while promoting an M1 phenotype. Mechanistically, finasteride upregulated ZBTB20, counteracting TNBC-mediated suppression of this M1-associated transcription factor. Our findings establish ZBTB20 as a key regulator of macrophage polarization in TNBC and introduce finasteride as a clinically viable agent to reverse TME immunosuppression. Targeting macrophage polarization via ZBTB20 modulation, particularly by repurposing finasteride, offers a promising therapeutic strategy for TNBC with immediate translational potential.
Insights
Triple-negative breast cancer (TNBC) is challenging due to its immunosuppressive tumor microenvironment. Finasteride drug repurposed to modulate ZBTB20 reverses M2 macrophage polarization, enhancing chemotherapy efficacy.
Area of Science:
- Immunology
- Oncology
- Computational Biology
Background:
- Triple-negative breast cancer (TNBC) poses significant therapeutic challenges due to its immunosuppressive tumor microenvironment (TME) and lack of targeted therapies.
- Macrophage polarization within the TME plays a critical role in TNBC progression and immune evasion.
Purpose of the Study:
- To develop a novel prognostic classifier for TNBC based on macrophage differentiation.
- To identify therapeutic agents capable of modulating macrophage polarization and reversing TME immunosuppression in TNBC.
Main Methods:
- Integrated analysis of scRNA-seq data from 24 TNBC patients using transcriptomics and machine learning.
- Development of a macrophage differentiation-based classifier (MMDCSS) using CD93, CHI3L1, and ZBTB20.
- Computational pharmacology to identify ZBTB20 modulators and in vitro/in vivo validation of finasteride's efficacy.
Main Results:
- The MMDCSS demonstrated high prognostic accuracy (C-index: 0.929, 3-year AUC: 0.907).
- Finasteride was identified as a ZBTB20 modulator, effectively reversing tumor-induced M2 macrophage polarization.
- Finasteride enhanced doxorubicin efficacy by reprogramming the TME, reducing M2 macrophages and promoting M1 phenotype, mechanistically via ZBTB20 upregulation.
Conclusions:
- ZBTB20 is a key regulator of macrophage polarization in TNBC, influencing the immunosuppressive TME.
- Finasteride shows potential as a repurposed drug to reverse TME immunosuppression in TNBC by targeting ZBTB20.
- Modulating macrophage polarization via ZBTB20 offers a promising and translationally relevant therapeutic strategy for TNBC.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...